Article Text

Download PDFPDF
Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study
  1. C. Marth*,
  2. G. H. Windbichler*,
  3. H. Hausmaninger,
  4. E. Petru,
  5. K. Estermann*,
  6. A. Pelzer* and
  7. E. Mueller-Holzner*
  1. *Department of Obstetrics and Gynaecology, Innsbruck Medical University, Innsbruck, Austria
  2. Department of Medical Oncology, Salzburg St. Johanns Hospital, Salzburg, Austria
  3. Department of Gynaecology, Graz Medical University, Graz, Austria
  1. Address correspondence and reprint requests to: Christian Marth, MD, PhD, Department of Obstetrics and Gynaecology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria. Email: christian.marth{at}


We have previously shown that interferon-gamma 1b (IFN-γ) in combination with cyclophosphamide and cisplatin significantly prolongs progression-free survival in ovarian cancer. In this phase I/II study, we examined if administration of IFN-γ is also safe in combination with the current standard treatment, paclitaxel and carboplatin. Thirty-four patients with newly diagnosed advanced epithelial ovarian cancer, FIGO stage III/IV, were treated for six to nine cycles with paclitaxel (175 mg/m2) and carboplatin (area under the curve [AUC] 5) every 3 weeks. IFN-γ was administered in an escalating dose from 6 days/cycle with 0.025 mg sc up to 9 days/cycle with 0.1 mg sc. As expected, administration of IFN-γ was associated with flu-like symptoms. Grade 3/4 neutropenia was observed in 74% (25 out of 34) of patients. Other side effects, in particular peripheral neuropathies, were within the previously observed ranges for the paclitaxel plus carboplatin combination. Overall response rate (complete or partial response) in patients who received either six or nine doses (0.1 mg) of IFN-γ/cycle (n = 28) was 71%. IFN-γ is safe in combination with carboplatin and paclitaxel for first-line treatment of patients with advanced ovarian cancer. This combination should be further evaluated as an immunotherapeutic treatment option for ovarian cancer.

  • carboplatin
  • interferon-γ
  • ovarian cancer
  • paclitaxel

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.